



The Diagnostic Specialist

Press Release

DIASORIN S.P.A., FOLLOWING ITS INCLUSION IN THE FTSE MIB INDEX, VOLUNTARILY ASKED TO BE REMOVED FROM THE “STAR” SEGMENT

Saluggia, July 11, 2011 – DiaSorin S.p.A., recently added to the components of the FTSE MIB Index, acting in pursuit of the Company’s best interest, began today, in concert with Borsa Italiana, the necessary procedures to obtain on a voluntary basis the cancellation of its STAR qualification, which it received on July 19, 2007 upon the initial listing of its common shares for trading on the markets organized and operated by Borsa Italiana S.p.A..

The inclusion of its stock in the FTSE MIB Index as of December 20, 2010 represents for DiaSorin a clear endorsement of the success it achieved in terms of growth and development over the past ten years and ensures that DiaSorin will continue to play in the Italian stock market the key role earned earlier with its inclusion in the STAR segment.

With a view to continuity, the Company announces that, in any case, it will continue to comply with the principles of corporate governance and the requirements of transparent communications proper of the STAR segment, maintaining the respective standards of transparency and corporate governance for the protection of all investors and continuing to implement the corporate governance procedures and best practices adopted until now.

As a result of its exiting the STAR segment, the Company will discontinue the use of a Specialist, effective July 19, 2011, which will be the expiration date of the mandate awarded for this purpose to Mediobanca S.p.A..



The Diagnostic Specialist

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 22 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it

Contacts:

Investor Relations Director

Laura Villa

DiaSorin S.p.A.

laura.villa@diasorin.it

+39 02 96474567

+39 348 1511542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 5901402